6855.HK

The latest: Ascentage Pharma Group International (6855.HK) announced on Tuesday it recently received a zero-deficiency report following a Good Manufacturing Practice (GMP) compliance audit of its global manufacturing center by a Qualified Person (QP) from the European Union (EU). The EU issued the report after an inspection over a four-day period.

Looking up: The report means the company’s global manufacturing center and quality management system comply with EU GMP standards, providing an important quality assurance benchmark.

Take Note: Ascentage’s core product, the leukemia drug olverembatinib, was commercialized in China last year. It may require some more time to be approved for overseas markets such as Europe.

Digging Deeper: Founded in 2009 and listed on the Hong Kong Stock Exchange in 2019, Ascentage is a China-based company that develops innovative drugs for oncology, hepatitis B and aging-related diseases. Its self-developed drug olverembatinib received conditional marketing approval from China’s National Medical Products Administration (NMPA) in November 2021, leading to a 652% jump in revenue to 210 million yuan ($30.5 million) in 2022. In January this year, the product was also included in the 2022 edition of China’s National Reimbursement Drug List under the nation’s national health plan, which will help increase its market share and boost future sales.

Market Reaction: Ascentage’s shares fell on Tuesday, closing down 4% at HK$22.70 by the midday break. The stock now trades in the middle of its 52-week range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Qudian abandons last mile delivery

Qudian: A slow-motion privatization?

The company said it is contemplating winding down its last-mile delivery service after stiff competition caused its revenue to plunge in the first quarter Key Takeaways: Qudian’s revenue fell by…
Yeahka secures bridgehead in U.S. payments market

Yeahka secures bridgehead in U.S. payments market

The Chinese fintech has cleared one of many regulatory hurdles to enter the U.S. digital payments business after gaining a state-level operating license Key Takeaways: After getting U.S. federal clearance,…
Sante makes infant nutritional products

Sainte Nutritional nurtures Hong Kong IPO

The Qingdao-based maker of food for special medical purposes is challenging international firms that still dominate the China market but could face tariff uncertainties Key Takeaways: Sainte Nutritional has filed…